Clinical exome sequencing is currently being used in diagnostics of various genetic disorders, but studies supporting its application in clinical setting are scarce. The aim of this study was to establish diagnostic and clinical utility of clinical exome sequencing in patients with moderate and severe global developmental delay/intellectual disability. Clinical diagnosis was made in 49 of 88 investigated patients, with overall diagnostic yield of 55.7%. Molecular findings are characterized in detail, including the impact of newly made diagnosis on clinical management. Several previously unreported genotype-phenotype correlations and 33 novel variants are described. Genetic and clinical data were shared through publicly available database. In conclusion, clinical exome sequencing allows identification of causative variants in a significant proportion of patients in investigated clinical subgroup. Compared to whole exome sequencing, it shows similar diagnostic and clinical utility with reduced costs, which could be of particular importance for institutions with limited resources.
RopersHH. Genetics of early onset cognitive impairment. Annu Rev Genomics Hum Genet. 2010;11:161–187.
2.
MoeschlerJBShevellM. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics. 2014;1;134(3):e903–e918.
3.
VissersLEGilissenCVeltmanJA. Genetic studies in intellectual disability and related disorders. Nat Rev Genet. 2016;17(1):9.
4.
BowlingKMThompsonMLAmaralMD, et al.Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Med. 2017;9(1):43.
5.
RehmHL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet. 2013;14(4):295.
6.
De LigtJWillemsenMHvan BonBW, et al.Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367:1921–1929.
7.
RauchAWieczorekDGrafE, et al.Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet. 2012;380:1674–1682.
8.
PajusaluSKahreTRoomereH, et al.Large gene panel sequencing in clinical diagnostics—results from 501 consecutive cases. Clin Genet. 2018;93(1):78–83.
9.
OkazakiTMurataMKaiM, et al.Clinical diagnosis of Mendelian disorders using a comprehensive gene-targeted panel test for next generation sequencing. Yonago Acta Med. 2016;59:118–125.
10.
ChérotEKerenBDubourgC, et al.Using medical exome sequencing to identify the causes of neurodevelopmental disorders: experience of 2 clinical units and 216 patients. Clin genet. 2018;93(3):567–576.
11.
GieldonLMackenrothLKahlertAK, et al.Diagnostic value of partial exome sequencing in developmental disorders. PLoS One. 2018;13(8):e0201041.
12.
AlesMLucaLMarijaV, et al.Phenotype-driven gene target definition in clinical genome-wide sequencing data interpretation. Genet Med. 2016;18(11):1102.
13.
De PristoMABanksEPoplinR, et al.A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491.
14.
San LucasFAWangGScheetPPengB. Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics. 2012;28(3):421–422.
15.
WangKLiMHakonarsonH. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
16.
KarczewskiKJFrancioliLCTiaoG, et al.Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. BioRxiv. 2019;1:531210.
17.
LiuXJianXBoerwinkleE. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat. 2013;34(9):E2393–E402.
18.
CingolaniPPlattsAWangLL, et al.A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012;6(2):80–92.
19.
DavydovEVGoodeDLSirotaMCooperGMSidowABatzoglouS. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol. 2010;6(12):e1001025.
20.
LandrumMJLeeJMRileyGR, et al.ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2013;42(D1):D980–D985.
21.
StromSPLeeHDasK, et al.Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory. Genet Med. 2014;16(7):510–515.
22.
RichardsSAzizNBaleS, et al.Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405.
23.
LekMKarczewskiKJMinikelEV, et al.Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285.
24.
HamoshAScottAFAmbergerJSBocchiniCAMcKusickVA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2005;33(suppl_1):D514–D517.
WuYWSullivanJMcDanielSS, et al.Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310–e1315.
27.
PleckoBPaulKPaschkeE, et al.Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat. 2007;28(1):19–26.
28.
NovyJMcWilliamsESisodiyaSM. Asystole in alternating hemiplegia with de novo ATP1A3 mutation. Eur J Hum Genet. 2014;57(1):37–39.
29.
HeinzenELSwobodaKJHitomiY, et al.De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet. 2012;44(9):1030.
30.
PleckoBPaulKMillsP, et al.Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology. 2014;82(16):1425–1433.
31.
RumpAHildebrandLTzschachA, et al.A mosaic maternal splice donor mutation in the EHMT1 gene leads to aberrant transcripts and to Kleefstra syndrome in the offspring. Eur J Hum Genet. 2013;21(8):887.
KentWJSugnetCWFureyTS, et al.The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006.
34.
MillerDTAdamMPAradhyaS, et al.Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749–764.
35.
SouthSTLeeCLambANHigginsAWKearneyHM. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. Genet Med. 2013;15(11):901.
36.
LeeHDeignanJLDorraniN, et al.Clinical exome sequencing for genetic identification of rare Mendelian disorders. Jama. 2014;312(18):1880–1887.
37.
YangYMuznyDMXiaF, et al.Molecular findings among patients referred for clinical whole-exome sequencing. Jama. 2014;312(18):1870–1879.
38.
StudyTDFitzgeraldTWGeretySS, et al.Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519(7542):223.
39.
WrightCFFitzgeraldTWJonesWD, et al.Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet. 2015;385(9975):1305–1314.
40.
ThevenonJDuffourdYMasurel-PauletA, et al.Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin Genet. 2016;89(6):700–707.
41.
VissersLEVan NimwegenKJSchievingJH, et al.A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. Genet Med. 2017;19(9):1055.
42.
ClarkMMStarkZFarnaesL, et al.Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med. 2018;3.
43.
KuperbergMLevDBlumkinL, et al.Utility of whole exome sequencing for genetic diagnosis of previously undiagnosed pediatric neurology patients. J Child Neurol. 2016;31(14):1534–1539.
44.
HelbigKLHagmanKDShindeDN, et al.Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med. 2016;18(9):898.
45.
TrujillanoDBertoli-avellaAMKumar KandaswamyK, et al.Clinical exome sequencing: results from 2819 samples reflecting 1000 families. Eur J Hum Genet. 2017;25(2):176–182.
46.
FarwellKDShahmirzadiLEl-khechenD, et al.Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med. 2015;17(7):578–586.
47.
PoseyJERosenfeldJAJamesRA, et al.Molecular diagnostic experience of whole-exome sequencing in adult patients. Genet Med. 2016;18(7):678–685.
48.
Doco-FenzyMLeroyCSchneiderA, et al.Early-onset obesity and paternal 2pter deletion encompassing the ACP1, TMEM18, and MYT1 L genes. Eur J Hum Genet. 2014;22(4):471.
49.
SalahshourifarIHalimASSulaimanWAAriffinRNorNNZilfalilBA. De novo interstitial deletion of 1q32. 2–q32. 3 including the entire IRF6 gene in a patient with oral cleft and other dysmorphic features. Cytogenet Genome Res. 2011;134(2):83–87.
50.
CardosoCLeventerRJWardHL, et al.Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13. 3. Am J Hum Genet. 2003;72(4):918–930.
51.
StrommePMangelsdorfMEShawMA, et al.Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet. 2002;30:441–445.
52.
KatoM. A new paradigm for West syndrome based on molecular and cell biology. Epilepsy Res. 2006;70:87–95.
53.
BowdinSGilbertABedoukianE, et al.Recommendations for the integration of genomics into clinical practice. Genet Med. 2016;18(11):1075.
